Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
This study is currently recruiting participants.
Verified January 2013
by Millennium Pharmaceuticals, Inc.
Study NCT01482962 Information provided by Millennium Pharmaceuticals, Inc.
First Received on November 28, 2011. Last Updated on January 27, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Relapsed Peripheral T-Cell Lymphoma
Additional conditions recognized in this trial
Lymphoma, T-Cell, Peripheral
More general conditions related to this trial
Immune System Diseases
Neoplasms by Histologic Type
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sponsors listed in this trial
Millennium Pharmaceuticals, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers